
VolitionRx Limited VNRX
$ 1.35
-1.82%
Quarterly report 2026-Q1
added 05-14-2026
VolitionRx Limited Depreciation & Amortization 2011-2026 | VNRX
Annual Depreciation & Amortization VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 984 K | 1.11 M | 1.15 M | 936 K | 945 K | 716 K | 677 K | 636 K | 528 K | 309 K | 236 K | 142 K | 146 K | 136 K | 119 K | 21.1 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 M | 21.1 K | 550 K |
Quarterly Depreciation & Amortization VolitionRx Limited
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 207 K | - | - | 252 K | - | - | - | 263 K | - | - | - | 272 K | - | 687 K | 450 K | 224 K | - | 709 K | 472 K | 227 K | - | 525 K | 359 K | 180 K | - | 510 K | 339 K | 168 K | - | 475 K | 318 K | 156 K | - | 371 K | 226 K | 93.3 K | - | 231 K | 152 K | 72.2 K | - | 164 K | 91.5 K | 40.2 K | - | 99.9 K | 63.6 K | 30.9 K | - | 109 K | 72.5 K | 36.4 K | - | 103 K | 69.8 K | 33 K | - | 77.6 K | 47.6 K | 23.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 709 K | 23.9 K | 225 K |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | ||
|
Quest Diagnostics Incorporated
DGX
|
570 M | $ 204.95 | 0.21 % | $ 22.7 B | ||
|
Celcuity
CELC
|
167 K | $ 87.79 | -5.18 % | $ 4.1 B | ||
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
24.1 M | $ 18.93 | 2.35 % | $ 583 M | ||
|
Co-Diagnostics
CODX
|
1.11 M | $ 4.22 | -6.33 % | $ 5.61 M | ||
|
Castle Biosciences
CSTL
|
40.8 M | $ 21.07 | -0.05 % | $ 611 M | ||
|
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
1.4 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
39.7 M | $ 131.33 | 0.93 % | $ 16.5 B | ||
|
CareDx, Inc
CDNA
|
15 M | $ 22.97 | 0.95 % | $ 1.22 B | ||
|
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | ||
|
ICON Public Limited Company
ICLR
|
383 M | $ 150.63 | -0.78 % | $ 11.8 B | ||
|
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | ||
|
Illumina
ILMN
|
270 M | $ 164.44 | 2.76 % | $ 25.5 B | ||
|
Interpace Biosciences
IDXG
|
425 K | $ 1.79 | 2.87 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
70.1 M | $ 102.1 | 2.12 % | $ 6.89 B | ||
|
Charles River Laboratories International
CRL
|
403 M | $ 190.0 | 0.08 % | $ 9.42 B | ||
|
Medpace Holdings
MEDP
|
27.2 M | $ 473.68 | 1.47 % | $ 13.7 B | ||
|
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 136.75 | -2.26 % | $ 23.4 B | ||
|
NeoGenomics
NEO
|
36.1 M | $ 11.69 | 2.19 % | $ 1.5 B | ||
|
Myriad Genetics
MYGN
|
53.7 M | $ 4.61 | 1.54 % | $ 427 M | ||
|
National Research Corporation
NRC
|
7.62 M | $ 20.0 | 1.27 % | $ 448 M | ||
|
Natera
NTRA
|
41.8 M | $ 218.15 | -2.1 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
13 M | $ 1.37 | -0.36 % | $ 411 M | ||
|
Personalis
PSNL
|
10 M | $ 9.71 | -0.41 % | $ 867 M | ||
|
Koninklijke Philips N.V.
PHG
|
1.12 B | $ 25.9 | -2.26 % | $ 24.6 B | ||
|
Senseonics Holdings
SENS
|
1.51 M | $ 7.17 | -3.45 % | $ 299 M | ||
|
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
2.02 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
87 K | $ 2.03 | -1.02 % | $ 4.66 M | ||
|
Twist Bioscience Corporation
TWST
|
24.9 M | $ 68.23 | -2.61 % | $ 4.08 B | ||
|
Laboratory Corporation of America Holdings
LH
|
681 M | $ 272.64 | 0.53 % | $ 22.7 B | ||
|
Thermo Fisher Scientific
TMO
|
1.05 B | $ 486.81 | -1.47 % | $ 184 B | ||
|
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
88.1 M | $ 368.54 | -0.7 % | $ 21.9 B | ||
|
Neogen Corporation
NEOG
|
119 M | $ 9.24 | -0.48 % | $ 2 B |